How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
MannKind's fair value estimate is held at US$7.50, signaling that the core price target framework is intact even as some inputs to the model are tweaked. Recent Street commentary helps explain why many analysts are clustering in the mid single digit to low double digit range, weighing Tyvaso DPI royalty risk against what Afrezza, Furoscix and the broader pipeline might contribute. As you read on, you will see what is driving this split view and how to track the next turns in MannKind's evolving story. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value MannKind. What Wall Street Has Been Saying ?? Bullish Takeaways H.C. Wainwright reiterates a Buy rating with a US$11 target, arguing that recent share price moves may have reset MannKind's value proposition and that 2026 internal catalysts could be important for Afrezza and the broader portfolio. Leerink and Wedbush both keep positive ratings, viewing recent vol
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- MannKind (MNKD) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- MannKind CEO purchases 100,000 shares; stock climbs [Seeking Alpha]Seeking Alpha
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/25/26 - Form 4
- 3/25/26 - Form 4
- 3/25/26 - Form 4
- MNKD's page on the SEC website